The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The company has been sold to Shinshin Pharmaceuticals
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The drug is also intended for the treatment of glioblastoma multiforme
The segment delivered strong sales growth of 20% YoY
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
The clinical research organisation located in Hyderabad is a USFDA inspected facility
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
Subscribe To Our Newsletter & Stay Updated
